Metrics as of 10/15/2026, 02:58 PM (Berlin time), refresh in progress.
BrainsWay Stock
BrainsWay Ltd.
Company data
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Country
- Israel
- CEO
- Hadar Levy
- Employees
- 129
- Market cap
- $451 M
- IPO
- 17/04/2019
BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep…
BrainsWay stock: price history
1D
-3.4%
1W
-0.9%
1M
-15.6%
6M
-27.2%
YTD
+21.0%
1Y
+51.8%
2Y
+144.9%
5Y
+194.4%
10Y
–
Next earnings date
Next earnings date
10/11/2026 (in 24 days)
Volatility around earnings
~51% stronger price swings than usual
Ask the agents about BrainsWay
Analyst assessment of BrainsWay
PRICE TARGET LOW
US$19.00
CONSENSUS
US$19.50
MEDIAN
US$19.50
PRICE TARGET HIGH
US$20.00
0
STRONG BUY
7
BUY
1
HOLD
0
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 10/09/2026
BrainsWay stock metrics
P/E
48.2
P/B
5.91
EV/EBITDA
60.8
RETURN ON EQUITY
3.5%
NET MARGIN
15.8%
DEBT/EQUITY
0.09
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
75.0%
FLOAT SHARES
29,421,761
AVG. DAILY VOLUME (30D)
105,986
Insider transactions (SEC)
Moiseyev Gilad
Moiseyev Gilad
Moiseyev Gilad
Roth Yiftach
Roth Yiftach
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about BrainsWay stock
What does BrainsWay do?
BrainsWay Ltd. is a company in the Healthcare sector, Medical - Specialties industry, headquartered in Israel.
The CEO is Hadar Levy, the company employs around 129 people.
The IPO was on 17/04/2019; the stock trades on NASDAQ under the ticker BWAY.
What do analysts say about BrainsWay stock?
8 analysts rate the stock, the consensus is Buy (as of 10/09/2026).
The average price target is US$19.50, ranging from US$19.00 to US$20.00, with a median of US$19.50.
This is an external assessment, not a statement by Market Jury.
When does BrainsWay report next?
The next earnings date is 10/11/2026.
Around past earnings, price swings were roughly 51% stronger than usual.
Does BrainsWay pay a dividend?
No, BrainsWay currently does not pay a dividend.
Which stocks are comparable to BrainsWay?
Comparable stocks include STERIS, QuidelOrtho, Mesa Laboratories, 908 Devices, Trinity Biotech, Teva Pharmaceutical Industries, Alpha Tau Medical and Eli Lilly and Company.
How can I get BrainsWay stock analyzed?
Clicking "Analyze stock" lets five strategies assess BrainsWay against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.